VIP (Vasoactive Intestinal Peptide) Research: VPAC Pharmacology and Circadian Biology

Vasoactive Intestinal Peptide (VIP) is a 28 amino acid neuropeptide belonging to the secretin/glucagon superfamily, expressed throughout the nervous system, gastrointestinal tract, and immune system. First isolated from porcine intestine by Said and Mutt in 1970, VIP has since been established as one of the most functionally diverse neuropeptides in mammalian biology — serving simultaneously as a neurotransmitter, neuromodulator, paracrine hormone, and immune signalling molecule.

Receptor Pharmacology

VIP activates three class B GPCRs: VPAC1 (VIPR1), VPAC2 (VIPR2), and PAC1 (ADCYAP1R1, which also responds to PACAP with higher affinity than VIP). VPAC1 and VPAC2 both couple to Gs, activating adenylyl cyclase and raising intracellular cAMP through PKA. PAC1 additionally couples to Gq in some cell types. VIP shows approximately equal affinity for VPAC1 and VPAC2 (Kd approximately 1nM for both), distinguishing it from PACAP which shows 1000-fold selectivity for PAC1.

Receptor distribution: VPAC1 is expressed in the SCN, hippocampus, lung, liver, small intestine, T lymphocytes, and many other tissues. VPAC2 is expressed in the SCN, thalamus, cortex, pancreas, skeletal muscle, mast cells, and eosinophils. The differential distribution means that tissue-specific VIP effects require receptor subtype attribution using selective pharmacological tools.

Selective pharmacology: VPAC1-selective agonist: [K15,R16,L27]-VIP(1-7)/GRF(8-27) (hybrid peptide). VPAC2-selective agonist: Ro-25-1553 (cyclic peptide). Pan-VPAC antagonist: VIP(6-28) (N-terminally truncated). These tools enable receptor-specific research in any cellular model expressing one or both VPAC subtypes.

Suprachiasmatic Nucleus and Circadian Biology

VIP's most critical physiological role may be its function in the suprachiasmatic nucleus (SCN) master circadian pacemaker. The SCN contains approximately 20,000 neurons in bilateral nuclei above the optic chiasm, which synchronise peripheral circadian clocks throughout the body through endocrine, autonomic, and behavioural outputs.

VIP is expressed in approximately 20-25% of SCN neurons — specifically the ventrolateral core region that receives direct retinal input via the retinohypothalamic tract. VIP neurons in the SCN core are activated by light signals arriving from intrinsically photosensitive retinal ganglion cells (ipRGCs) expressing melanopsin, and release VIP onto the larger dorsomedial shell population expressing VPAC2.

The essential role of VIP/VPAC2 signalling in SCN network synchrony was established by Harmar et al. (Cell, 2002) showing that VPAC2 knockout mice have severely disrupted circadian rhythms — loss of consolidated rest-activity cycles, loss of molecular oscillation synchrony in the SCN, and failure to re-entrain to phase-shifted light-dark cycles. This landmark finding established VIP/VPAC2 as the primary coupling signal in the SCN network oscillator.

SCN slice research protocol: Prepare acute coronal hypothalamic slices (400µm) from adult C57BL/6 mice in ice-cold sucrose ACSF. Transfer to recording chamber with standard ACSF (95% O2/5% CO2, 34°C). Using multi-electrode arrays (MEA), record spontaneous multi-unit activity (MUA) from bilateral SCN over 24-72 hours to characterise the circadian firing rhythm. Apply VIP (100nM-1µM) via bath perfusion at defined circadian times. Quantify phase shifts of subsequent firing rhythms by fitting a sinusoidal function to the MUA time series.

Immunomodulation Research

VIP receptors are expressed on T lymphocytes (VPAC1, VPAC2), macrophages (VPAC1), dendritic cells (VPAC1, VPAC2), NK cells, and mast cells. Through Gs/cAMP/PKA signalling, VIP modulates multiple immune functions.

Macrophage research: LPS-stimulated RAW264.7 macrophages or bone marrow-derived macrophages (BMDMs) pre-treated with VIP (1-100nM) show reduced TNF-alpha, IL-6, IL-12, and nitric oxide production at 24 hours. This anti-inflammatory effect operates through cAMP/PKA-mediated suppression of NFkB p65 nuclear translocation. Measure: cytokines by ELISA in conditioned medium; NFkB nuclear localisation by immunofluorescence; phospho-IkBα by Western blot; nitric oxide by Griess reagent.

Dendritic cell biology: VIP treatment of monocyte-derived DCs shifts maturation toward a tolerogenic phenotype — reduced CD80, CD86, CD40 upregulation in response to LPS; reduced IL-12p70 production; increased IL-10 production. This tolerogenic DC phenotype drives regulatory T cell (Treg) induction rather than effector T cell priming.

Gastrointestinal Research

VIP functions as the primary non-adrenergic non-cholinergic (NANC) inhibitory neurotransmitter in the gastrointestinal tract. VIPergic neurons in the myenteric plexus release VIP to drive smooth muscle relaxation (lower oesophageal sphincter, pyloric sphincter, intestinal smooth muscle), intestinal chloride secretion through VPAC1 on enterocytes, and pancreatic enzyme and bicarbonate secretion.

Intestinal smooth muscle relaxation research uses pre-contracted ileal smooth muscle strips (carbachol 1µM pre-contraction) in organ bath preparations. Cumulative VIP concentration-response curves (1nM-10µM) measure relaxation amplitude as percentage of maximum carbachol contraction. Compare with PACAP (higher PAC1 affinity) to dissect VPAC versus PAC1 contributions to smooth muscle pharmacology.

Key Published Research

• Said SI, Mutt V. "Polypeptide with broad biological activity: isolation from small intestine." Science, 1970. PMID: 4908048
• Harmar AJ, et al. "The VPAC2 receptor is essential for circadian function in the mouse suprachiasmatic nuclei." Cell, 2002. PMID: 12419249
• Delgado M, et al. "Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor α transcriptional activation by regulating nuclear factor-κB." Journal of Biological Chemistry, 2000. PMID: 10829054

View VIP (Vasoactive Intestinal Peptide) →

For laboratory and analytical research purposes only. Not for human or veterinary use.

VIP and Neuroinflammation Research

VIP's anti-inflammatory signalling in peripheral immune cells extends to central nervous system microglia — the resident brain macrophages. Microglial VPAC1 and VPAC2 expression provides a mechanism for VIP to modulate neuroinflammatory responses in the CNS.

For neuroinflammation research using BV2 microglial cells or primary microglia isolated from postnatal rat brain: activate with LPS (1µg/mL) for 24 hours to produce M1-like inflammatory polarisation characterised by elevated TNF-alpha, IL-6, IL-12, and iNOS/nitric oxide. Pre-treat or co-treat with VIP (1-100nM). Measure inflammatory mediators by ELISA and Griess reagent (nitric oxide). Confirm VPAC receptor involvement using VIP(6-28) antagonist (1µM pre-treatment) — if VIP(6-28) abolishes the anti-inflammatory effect, this confirms VPAC-mediated rather than off-target signalling.

Microglial morphology analysis by immunofluorescence (Iba-1 staining): M1 activated microglia show amoeboid, retracted morphology; M2 anti-inflammatory microglia show ramified, process-bearing morphology. VIP treatment may shift microglial morphology toward M2, quantifiable by automated analysis of cell perimeter, process length, and process number per cell.

VIP and Intestinal Motility

The enteric nervous system contains more neurons than the spinal cord, and VIP is one of its primary inhibitory neurotransmitters. VIPergic interneurons in the myenteric plexus drive descending inhibition — relaxing the circular muscle layer ahead of a peristaltic contraction — and mediate receptive relaxation of the gastric fundus during food ingestion.

Intestinal smooth muscle strip pharmacology provides direct measurement of VIP's enteric effects. Mount guinea pig ileum longitudinal muscle-myenteric plexus (LMMP) or circular muscle strips (0.5×3cm) in 37°C Krebs buffer organ bath with isometric force transducer. Pre-contract with carbachol (10µM). Apply VIP cumulatively (0.1nM-10µM) and record relaxation. Calculate pEC50 from the sigmoid concentration-response curve. Include VPAC1-selective antagonist [Ala11,22,28]-VIP in parallel to determine VPAC1 versus VPAC2 contribution to smooth muscle relaxation.

VIP Structure-Activity Relationships

VIP's 28 amino acid sequence has been systematically truncated and modified to characterise the receptor-binding pharmacophore. Residues 1-12 are sufficient for receptor binding; the N-terminal His1 is essential for receptor activation (His1-substituted VIP binds but does not activate VPAC receptors). Residues 1-7 constitute the activation domain; residues 8-28 constitute the receptor-contact affinity domain.

This structure-activity knowledge contextualises VIP research: truncated VIP analogues (VIP(2-28), VIP(6-28)) serve as antagonists because they retain receptor binding without activation capability. VIP(6-28) is the most widely used VPAC antagonist in published research. Including VIP(6-28) in VIP research experiments provides pharmacological evidence for VPAC-mediated effects and distinguishes them from potential receptor-independent VIP biology.

VIP and Pituitary Biology

Beyond the SCN and immune system, VIP plays important roles in anterior pituitary hormone regulation. VIP-containing neurons project from the hypothalamus to the anterior pituitary, and VPAC receptors are expressed on pituitary cell types including lactotrophs (prolactin-secreting), thyrotrophs (TSH-secreting), and gonadotrophs (LH/FSH-secreting).

VIP is one of the primary hypothalamic prolactin-releasing factors — acting through VPAC1 on lactotrophs to stimulate prolactin secretion via Gs/cAMP/PKA signalling. This VIP-driven prolactin release contributes to the suckling-induced prolactin surge during lactation and to stress-associated hyperprolactinaemia. Research examining VIP effects on prolactin secretion uses primary pituitary cell cultures (rat or bovine anterior pituitary disaggregated by enzymatic digestion) measuring prolactin by RIA or ELISA in conditioned medium at 15-60 minutes after VIP application. Comparison with TRH (thyrotropin-releasing hormone, an independent prolactin-releasing factor acting through Gq/PLC) allows mechanistic dissection of cAMP-dependent versus calcium-dependent prolactin release pathways.

VIP and Neuroprotection

VIP has been characterised as a neuroprotective peptide in multiple published models — protecting neurons from excitotoxicity, oxidative stress, and beta-amyloid peptide toxicity through VPAC receptor-mediated Gs/cAMP/PKA signalling. PKA activation in neurons phosphorylates CREB (cAMP response element binding protein) at Ser133, driving transcription of CREB target genes including BDNF, Bcl-2, and antioxidant enzymes.

For VIP neuroprotection research: primary cortical neurons (embryonic day 18, culture to DIV14) challenged with glutamate (100µM, 20 minutes) to produce excitotoxic NMDA receptor-mediated calcium overload and neuronal death. VIP pre-treatment (1-100nM, 1 hour before glutamate challenge). Measure viability at 24 hours by calcein-AM/ethidium homodimer. Confirm VPAC-dependence using VIP(6-28) antagonist. Downstream CREB phosphorylation by Western blot (Ser133) at 30 minutes confirms the Gs/cAMP/PKA/CREB neuroprotective pathway is engaged at the neuroprotective concentration range.

VIP also interacts with the ADNF (activity-dependent neurotrophic factor) pathway — VIP stimulates astrocytes to produce ADNF (SALLRSIPA), a glial neuroprotective factor that protects neurons from beta-amyloid toxicity at femtomolar concentrations. This VIP-astrocyte-ADNF axis represents a paracrine neuroprotection circuit that can be studied using astrocyte-conditioned medium transfer experiments.